New York/Mumbai: Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS) a leading global IT services, consulting and business solutions organization, announced that it has been designated as a Leader in Worldwide Life Sciences R&D Risk-Based Monitoring by global market intelligence firm, IDC, in the “IDC MarketScape: Worldwide Life Science R&D Risk-Based Monitoring 2015 Vendor Assessment,” (doc #HI255628, April 2015) report.
The report evaluated eight leading IT services vendors with significant RBM expertise, across a number of capability and strategy measures such as, offering roadmap, portfolio strategy, customer base, engagement capability, pricing model, investment, growth strategy, and more. IDC MarketScape’s criteria selection, weightings and vendor scores, represent well-researched IDC judgments about the market and vendors through structured discussions, surveys and interviews with market leaders, participant buyers and end users.
TCS was recognized as a leader for its overall capability and extensive experience working with life sciences companies across all three sections of the industry: pharmaceutical, biotech and medical devices. The report further states that TCS brings a full spectrum of strong operational service capabilities to the clinical trial space, with particular strength in data management, analytics, systems integration, and RBM-specific operational processes.
“The full implementation of RBM across the clinical trial life cycle requires a variety of service capabilities, ranging from RBM strategic consulting to RBM-specific IT infrastructure support to RBM specific BPO,” said Dr. Alan Louie, Research Director, Clinical Development Strategy and Technology, IDC Health Insights. “TCS’ strong technical focus, success with top life science companies, and growing experience in the RBM space, make the company a strong contender for companies seeking a service organization to help operationalize RBM into their clinical processes.”
“With increasing complexities in the life sciences R&D market, organizations are working aggressively towards reducing overall trial costs, which has led to a rapid adoption of risk-based monitoring in clinical trials,” said Debashis Ghosh, President of Life Sciences, Manufacturing and Energy & Resources at TCS. “We are honored to be recognized as a Leader in such an integral space by IDC Health Insights.”
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Copyright © 2014 - 2022 The Global Indian New Network (TGINN)